Skip to Content
Merck

Skip To

M6191

GW9662

>98% (HPLC), PPARγ antagonist, powder

Synonym(s):

2-Chloro-5-nitro-N-phenylbenzamide

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View
Pack SizeSKUAvailabilityPrice

About This Item

Empirical Formula (Hill Notation):
C13H9ClN2O3
CAS Number:
Molecular Weight:
276.68
UNSPSC Code:
51111800
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Assay:
>98% (HPLC)
Form:
powder
Quality level:
Pricing and availability is not currently available.
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist


Product Name

GW9662, >98% (HPLC)

Quality Level

assay

>98% (HPLC)

form

powder

color

white

solubility

DMSO: 26 mg/mL, H2O: insoluble

storage temp.

2-8°C

SMILES string

[O-][N+](=O)c1ccc(Cl)c(c1)C(=O)Nc2ccccc2

InChI

1S/C13H9ClN2O3/c14-12-7-6-10(16(18)19)8-11(12)13(17)15-9-4-2-1-3-5-9/h1-8H,(H,15,17)

InChI key

DNTSIBUQMRRYIU-UHFFFAOYSA-N

Gene Information

human ... PPARG(5468)

Application

GW9662 has been used as a peroxisome proliferator activated receptor γ (PPARγ) antagonist in human pluripotent stem cells, in phenylephrine stimulated cardiomyocytes and to inhibit the protective effect of telmisartan pheochromocytoma, PC12 cells.[1]

Biochem/physiol Actions

GW9662 is an irreversible PPARγ antagonist. GW9662 inhibits connective tissue growth factor and activation of CD36 by IL-4.
GW9662 is an irreversible PPARγ antagonist; inhibits connective tissue growth factor, and activation of CD36 by IL-4.
GW9662 (2-chloro-5-nitrobenzanilide) binds to the ligand binding site of the peroxisome proliferator activated receptor γ (PPARγ) and results in the inhibition of adipocyte differentiation. It favors cell growth suppression in breast cancer cell lines even in the presence of PPARγ agonist rosiglitazone. It stimulates M2c macrophages differentiation and triggers growth arrest-specific 6 (Gas6) expression. GW9662 co treatment with other PPARγ ligands elicits antiproliferative effects on the glioblastoma stem cells and could be a potent therapeutic agent.

Features and Benefits

This compound is featured on the Nuclear Receptors (PPARs) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.

Legal Information

Sold for research purposes only, under agreement from Glaxo­Smith­Kline

Compare Similar Items

View Full Comparison

Show Differences

1 of 1

This Item
G0673G7423SML2901
form

powder

form

powder

form

powder

form

powder

assay

>98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥98% (HPLC)

Quality Level

200

Quality Level

100

Quality Level

100

Quality Level

100

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

storage temp.

2-8°C

solubility

DMSO: 26 mg/mL, H2O: insoluble

solubility

DMSO: >20 mg/mL

solubility

DMSO: ≥10 mg/mL

solubility

DMSO: 2 mg/mL, clear

color

white

color

off-white to tan

color

white to off-white

color

faint yellow to dark orange


Storage Class

11 - Combustible Solids

wgk

WGK 3



Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library



Efstathia Papageorgiou et al.
Molecular medicine (Cambridge, Mass.), 14(7-8), 403-411 (2008-05-14)
PPARgamma, a member of the peroxisome proliferator-activated receptor family, is overexpressed in prostate cancer. Natural and synthetic ligands of PPARgamma via genomic and nongenomic actions promote cell cycle arrest and apoptosis of several prostate cancer cells, in vitro. Insulin-like growth
The PPAR-gamma antagonist GW9662 elicits differentiation of M2c-like cells and upregulation of the MerTK/Gas6 axis: a key role for PPAR-gamma in human macrophage polarization
Zizzo G and Cohen PL
Journal of Inflammation, 12(1), 36-36 (2015)
GW9662, a potent antagonist of PPARgamma, inhibits growth of breast tumour cells and promotes the anticancer effects of the PPARgamma agonist rosiglitazone, independently of PPARgamma activation
Seargent JM, et al.
British Journal of Pharmacology, 143(8), 933-937 (2004)



Global Trade Item Number

SKUGTIN
M6191-25MG04061832954561
M6191-5MG04061834060758

Questions

  1. GW9662 25mg을 구입해서 사용하고 있는데, 혹시 25mg 정량이 담겨져 오는걸까요? powder를 무게 재기 어려워서 그냥 vial에 바로 DMSO를 추가해서 쓸 수 있을까해서요!

    1 answer
    1. Yes, DMSO can be added directly to the vial. It is recommended to pipet up and down a few times to ensure that all the material is solubilized in DMSO.

      Helpful?

Reviews

No rating value

Active Filters